Development of prostrate cancer vaccine using PAP as target antigen

0044 English OPEN
Javad, JMS;
(2014)

Treatment options for patients with advanced prostate cancer (PC) still remain limited and rarely curative. The prostatic acid phosphatase (PAP) is prostate specific protein over-expressed in more than 90% of prostate tumours. Although an FDA-approved vaccine for the tr... View more
  • References (16)
    16 references, page 1 of 2

    3.2.1. Screening for PAP epitopes for vaccine design...........................79

    3.2.2. Enhanced IFNγ response seen for the selected PAP epitopes after

    optimised immunisation regime………………………………...82

    3.2.3. Assessment of optimum peptide concentration for PAP-114-128

    epitope…………………………………………………………..84

    3.2.4. ELISA confirms PAP-114-128 peptide specific IFNγ production

    by C57Bl/6 mouse splenocytes post- immunization……...…….87

    3.2.5. PAP-114-128 elicits a CD8 specific cytotoxic response and CD4

    specific proliferative response in C57Bl/6 mice………………..88

    3.2.6. Generation of dextramer positive peptide specific CD8+ T-cells by

  • Metrics
Share - Bookmark